JP2023078311A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023078311A5 JP2023078311A5 JP2023043678A JP2023043678A JP2023078311A5 JP 2023078311 A5 JP2023078311 A5 JP 2023078311A5 JP 2023043678 A JP2023043678 A JP 2023043678A JP 2023043678 A JP2023043678 A JP 2023043678A JP 2023078311 A5 JP2023078311 A5 JP 2023078311A5
- Authority
- JP
- Japan
- Prior art keywords
- invention described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020106501 | 2020-06-19 | ||
| JP2020106501 | 2020-06-19 | ||
| JP2022531930A JP7250219B2 (ja) | 2020-06-19 | 2021-06-18 | 血管新生阻害剤と組み合わせて使用するための抗ｔ細胞抗原結合分子 |
| PCT/JP2021/023149 WO2021256555A1 (ja) | 2020-06-19 | 2021-06-18 | 血管新生阻害剤と組み合わせて使用するための抗ｔ細胞抗原結合分子 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022531930A Division JP7250219B2 (ja) | 2020-06-19 | 2021-06-18 | 血管新生阻害剤と組み合わせて使用するための抗ｔ細胞抗原結合分子 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023078311A JP2023078311A (ja) | 2023-06-06 |
| JP2023078311A5 true JP2023078311A5 (https=) | 2024-06-26 |
Family
ID=79268097
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022531930A Active JP7250219B2 (ja) | 2020-06-19 | 2021-06-18 | 血管新生阻害剤と組み合わせて使用するための抗ｔ細胞抗原結合分子 |
| JP2023043678A Withdrawn JP2023078311A (ja) | 2020-06-19 | 2023-03-20 | 血管新生阻害剤と組み合わせて使用するための抗ｔ細胞抗原結合分子 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022531930A Active JP7250219B2 (ja) | 2020-06-19 | 2021-06-18 | 血管新生阻害剤と組み合わせて使用するための抗ｔ細胞抗原結合分子 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230235056A1 (https=) |
| EP (1) | EP4186527A4 (https=) |
| JP (2) | JP7250219B2 (https=) |
| KR (2) | KR20230152789A (https=) |
| CN (1) | CN115768478A (https=) |
| AU (1) | AU2021292932A1 (https=) |
| BR (1) | BR112022025536A2 (https=) |
| CA (1) | CA3180951A1 (https=) |
| CL (1) | CL2022003622A1 (https=) |
| CR (1) | CR20230014A (https=) |
| IL (1) | IL299127A (https=) |
| MX (1) | MX2022015764A (https=) |
| PE (1) | PE20230435A1 (https=) |
| TW (1) | TW202214286A (https=) |
| WO (1) | WO2021256555A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS67768B1 (sr) | 2010-11-30 | 2026-03-31 | Chugai Pharmaceutical Co Ltd | Terapijski agens koji indukuje citotoksičnost |
| WO2025120867A1 (en) * | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025167982A1 (zh) * | 2024-02-08 | 2025-08-14 | 上海翰森生物医药科技有限公司 | 抗体药物偶联物和抗vegf抗体的联合应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773719A (en) | 1966-12-06 | 1973-11-20 | Hoffmann La Roche | 2-aminoxy-2'-acyl-acetanilide |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| ES2292236T3 (es) | 1998-04-02 | 2008-03-01 | Genentech, Inc. | Variantes de anticuerpos y sus fragmentos. |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CN101289511A (zh) | 2000-04-11 | 2008-10-22 | 杰南技术公司 | 多价抗体及其应用 |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP3263596A1 (en) | 2002-12-16 | 2018-01-03 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| WO2008027236A2 (en) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
| US8337854B2 (en) | 2007-04-04 | 2012-12-25 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Monoclonal antibodies against dengue and other viruses with deletion in Fc region |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| RS67768B1 (sr) | 2010-11-30 | 2026-03-31 | Chugai Pharmaceutical Co Ltd | Terapijski agens koji indukuje citotoksičnost |
| CN118440206A (zh) | 2014-04-07 | 2024-08-06 | 中外制药株式会社 | 免疫活化抗原结合分子 |
| MA40764A (fr) * | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| US11072666B2 (en) * | 2016-03-14 | 2021-07-27 | Chugai Seiyaku Kabushiki Kaisha | Cell injury inducing therapeutic drug for use in cancer therapy |
| JP7125347B2 (ja) | 2016-08-22 | 2022-08-24 | 中外製薬株式会社 | ヒトｇｐｃ３ポリペプチドを発現する遺伝子改変非ヒト動物 |
| WO2018093821A1 (en) * | 2016-11-15 | 2018-05-24 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| WO2018183888A2 (en) * | 2017-03-31 | 2018-10-04 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling |
-
2021
- 2021-06-18 PE PE2022002932A patent/PE20230435A1/es unknown
- 2021-06-18 US US18/010,615 patent/US20230235056A1/en active Pending
- 2021-06-18 MX MX2022015764A patent/MX2022015764A/es unknown
- 2021-06-18 IL IL299127A patent/IL299127A/en unknown
- 2021-06-18 CA CA3180951A patent/CA3180951A1/en active Pending
- 2021-06-18 TW TW110122300A patent/TW202214286A/zh unknown
- 2021-06-18 CN CN202180043015.4A patent/CN115768478A/zh active Pending
- 2021-06-18 KR KR1020237036198A patent/KR20230152789A/ko active Pending
- 2021-06-18 EP EP21825999.2A patent/EP4186527A4/en not_active Withdrawn
- 2021-06-18 WO PCT/JP2021/023149 patent/WO2021256555A1/ja not_active Ceased
- 2021-06-18 AU AU2021292932A patent/AU2021292932A1/en not_active Abandoned
- 2021-06-18 CR CR20230014A patent/CR20230014A/es unknown
- 2021-06-18 JP JP2022531930A patent/JP7250219B2/ja active Active
- 2021-06-18 KR KR1020227039674A patent/KR102594943B1/ko active Active
- 2021-06-18 BR BR112022025536A patent/BR112022025536A2/pt unknown
-
2022
- 2022-12-16 CL CL2022003622A patent/CL2022003622A1/es unknown
-
2023
- 2023-03-20 JP JP2023043678A patent/JP2023078311A/ja not_active Withdrawn